Rigetti's Beaten-Down Label Is Doing Work the Numbers Don't Support

Rigetti's second-quarter print did what the company hoped: revenue nearly tripled. Total revenue for the quarter was $5.1 million, up 185% from $1.8 million a year earlier. That growth is real. It is also doing a lot of work in the market's head that the rest of the financials do not support — and most of what you own at $15 has nothing to do with that revenue line.

Here is the read, before the conclusion: a stock that has never produced free cash flow is not "cheap" just because it fell. Let me show you why.

The discount is against a high, not against a business

Rigetti shares are trading around $15, roughly a three-quarters drawdown from the 52-week high of $58.15. The instinct when you see a name fall that far is to call it "beaten down" and hunt for a bargain. But a discount only means something when you measure it against a business that puts cash in its pocket. Rigetti is not that business yet.

For all of 2025, Rigetti generated $7.1 million in revenue — and that was down about a third from the year before. The strong second quarter lifts the trailing picture, but the base is tiny. Set that against a market capitalization of about $5.15 billion (roughly 331 million shares at ~$15) and the arithmetic is stark: the company is priced at on the order of 700 times last year's revenue. There is no version of "cheap" that comes out of that number. A high multiple is not a risk that gets smaller when the stock falls; it is a bet on a future that has to actually arrive.

What the quarter showed underneath the growth headline matters more than the headline. The operating loss widened to $28.1 million, from about $20 million a year earlier, and operating expenses jumped 48% to $30.3 million as Rigetti pours money into engineering, chip design, and refrigeration infrastructure. Gross margin improved to about 43% from about 31% — a genuine operating gain — but a 43% margin on $5 million of revenue is not a business. It is a lab with a billing statement.

What you actually own is the cash, not the revenue

The number that decides whether Rigetti survives is not revenue. At June 30, the company held $541.3 million in cash and investments, with no debt. That pile is what keeps the roadmap alive. Against an operating burn of roughly $28 million a quarter, that is on the order of four-plus years of runway — before you count the fact that the burn is accelerating, not shrinking, as spending climbs.

That is the honest shape of the investment. You are not buying a company whose free cash flow is about to inflect. Rigetti has no free cash flow, and the losses are widening rather than narrowing — which is the opposite of the "improving underneath the surface" setup a true beaten-down inflection is supposed to look like. What you are buying is a funded option on a technology the company itself concedes is years from commercialization. Management's own framing is that revenue stays in the "low single-digit millions" in the near term, with "continued losses and uneven revenue." The cash is the asset. The roadmap is the hope. The revenue, for now, is the receipt.

Some people reach for a discount-rate model to justify a price like this. That is the illusion of control. The cash balance, not a spreadsheet, is the only thing currently standing between the science and a going-concern question.

The proof that would make this real — and the line that breaks it

So what would change the story? Not the next revenue beat. The near-term dollars that are actually promised are still government- and policy-anchored, and smaller than a single quarter's burn. An $8.4 million order for a 108-qubit system to India's C-DAC is expected to be recognized in the fourth quarter, after installation and acceptance testing. A letter of intent — not yet a signed contract — with the U.S. Department of Commerce covers up to $100 million over three years under the CHIPS Act, in exchange for a government equity stake. A full Novera system for Hewlett Packard Enterprise and the Pittsburgh Supercomputing Center is expected in 2027.

The one proof point that would make the "old story" — Rigetti as a well-funded lab — stale is a signed, multi-year order backlog: the CHIPS letter of intent converting to a real contract, plus recurring commercial system sales, large enough to be recognized revenue. Until that backlog exists, "commercial customers are replacing government" is partly narrative. The 10-Q still shows a single customer at 64% of Q2 revenue and government entities at about 18% (down, but present), and the largest items in the pipeline remain policy programs.

The line that breaks the thesis is equally concrete. The $541 million is a shrinking asset if operating spend keeps climbing 48% a quarter. If the CHIPS deal stalls, or the company must refinance that runway with a dilutive raise — a down-round, where new shares are sold below the current price and thin every existing holder — the story breaks even if the science works. The peer frame sharpens the point: the sector leader, IonQ, reported about $80 million in its most recent quarter, roughly fifteen times Rigetti's. Rigetti is one of only three companies with gate-based systems over 100 qubits, which is a real claim; it is also a reminder that the market has already picked a favorite.

My read: this is not the inflection this kind of analysis is built for. No free cash flow, losses widening, and a "beaten down" label that is doing work the numbers do not support. That does not make the stock wrong — a small, fully understood position on a 2028-to-2030 quantum-infrastructure future is a legitimate speculative bet if you know exactly what you are buying. But the metric that resolves it is not the next 185% growth print. It is the signed order backlog, and whether the cash balance reaches the roadmap without a down-round. Watch that line, not the multiple.